Mehran B Yusuf1, Jeremy Gaskins2, Mark J Amsbaugh3, Shiao Woo1, Eric Burton4. 1. Department of Radiation Oncology, University of Louisville Hospital, Kentucky, USA. 2. Department of Bioinformatics and Biostatistics, University of Louisville, Kentucky, USA. 3. Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA. 4. Division of Neuro-Oncology, Department of Neurology, University of Louisville, Kentucky, USA.
Abstract
BACKGROUND: Though conventionally fractionated chemoradiation (CRT) is well tolerated by selected patients with newly diagnosed glioblastoma (GBM), adverse health-related and nonhealth-related factors can lead to unplanned interruptions in treatment. The effects of prolonged time to completion (TTC) of radiation therapy (RT) on overall survival (OS) for these patients are unclear. METHODS: The National Cancer Database (NCDB) was queried for all adult patients with newly diagnosed GBM undergoing surgical resection followed by adjuvant CRT with conventionally fractionated RT (6000-6600 cGy in 30-33 fractions) from 2005 to 2012. TTC was defined as the interval from first to last fraction of RT. Recursive partitioning analysis (RPA) was used to determine a threshold for TTC of adjuvant RT. Cox proportional hazards modeling was used to identify covariates associated with OS. RESULTS: A total of 13489 patients were included in our cohort. Patients who completed adjuvant RT within the RPA-defined threshold of 46 days from initiation of RT (median OS: 14.0 months, 95% confidence interval (CI) 13.7 to 14.3 months) had significantly improved OS compared to patients with TTC of 47 days or greater (median OS: 12.0 months, 95% CI 11.4 to 12.6 months, P < .001). Delays in completing adjuvant RT were relatively common, with 15.0% of patients in our cohort having a TTC of RT of 47 days or greater. CONCLUSIONS: Delays in completing adjuvant RT were associated with a worse survival outcome. Any unnecessary delays in completing adjuvant RT should be minimized while ensuring the safe delivery of therapy.
BACKGROUND: Though conventionally fractionated chemoradiation (CRT) is well tolerated by selected patients with newly diagnosed glioblastoma (GBM), adverse health-related and nonhealth-related factors can lead to unplanned interruptions in treatment. The effects of prolonged time to completion (TTC) of radiation therapy (RT) on overall survival (OS) for these patients are unclear. METHODS: The National Cancer Database (NCDB) was queried for all adult patients with newly diagnosed GBM undergoing surgical resection followed by adjuvant CRT with conventionally fractionated RT (6000-6600 cGy in 30-33 fractions) from 2005 to 2012. TTC was defined as the interval from first to last fraction of RT. Recursive partitioning analysis (RPA) was used to determine a threshold for TTC of adjuvant RT. Cox proportional hazards modeling was used to identify covariates associated with OS. RESULTS: A total of 13489 patients were included in our cohort. Patients who completed adjuvant RT within the RPA-defined threshold of 46 days from initiation of RT (median OS: 14.0 months, 95% confidence interval (CI) 13.7 to 14.3 months) had significantly improved OS compared to patients with TTC of 47 days or greater (median OS: 12.0 months, 95% CI 11.4 to 12.6 months, P < .001). Delays in completing adjuvant RT were relatively common, with 15.0% of patients in our cohort having a TTC of RT of 47 days or greater. CONCLUSIONS: Delays in completing adjuvant RT were associated with a worse survival outcome. Any unnecessary delays in completing adjuvant RT should be minimized while ensuring the safe delivery of therapy.
Entities:
Keywords:
glioblastoma; prolonged radiotherapy; time to completion; treatment interruptions; treatment time
Authors: Mitchell Machtay; Chuanchieh Hsu; Ritsuko Komaki; William T Sause; R Suzanne Swann; Corey J Langer; Roger W Byhardt; Walter J Curran Journal: Int J Radiat Oncol Biol Phys Date: 2005-05-31 Impact factor: 7.038
Authors: M D Groves; M H Maor; C Meyers; A P Kyritsis; K A Jaeckle; W K Yung; R E Sawaya; K Hess; J M Bruner; P Peterson; V A Levin Journal: Int J Radiat Oncol Biol Phys Date: 1999-08-01 Impact factor: 7.038
Authors: Ravi D Rao; Stephan D Thomé; Judith O'Fallon; John D Earle; Robert P Dinapoli; Jan C Buckner Journal: Int J Radiat Oncol Biol Phys Date: 2002-06-01 Impact factor: 7.038
Authors: David I Rosenthal; Li Liu; Jason H Lee; Neha Vapiwala; Ara A Chalian; Gregory S Weinstein; Irina Chilian; Randal S Weber; Mitchell Machtay Journal: Head Neck Date: 2002-02 Impact factor: 3.147
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Angelique E Sijben; John B McIntyre; Gloria B Roldán; Jacob C Easaw; Elizabeth Yan; Peter A Forsyth; Ian F Parney; Anthony M Magliocco; Hans Bernsen; J Gregory Cairncross Journal: J Neurooncol Date: 2008-04-09 Impact factor: 4.130